Inogen (NASDAQ:INGN) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Inogen (NASDAQ:INGN) in a research report sent to investors on Friday morning,Benzinga reports.

Separately, StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th.

Inogen Trading Up 17.2 %

Shares of Inogen stock traded up $1.63 on Friday, reaching $11.09. 937,866 shares of the company were exchanged, compared to its average volume of 158,190. The stock has a fifty day moving average price of $9.95 and a 200-day moving average price of $9.39. The firm has a market capitalization of $263.04 million, a price-to-earnings ratio of -4.93 and a beta of 1.04. Inogen has a fifty-two week low of $4.59 and a fifty-two week high of $13.33.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.31. The business had revenue of $88.77 million for the quarter, compared to the consensus estimate of $82.50 million. Inogen had a negative net margin of 28.30% and a negative return on equity of 45.37%. Inogen’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.42) earnings per share. On average, equities analysts anticipate that Inogen will post -1.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in INGN. Inspire Advisors LLC acquired a new stake in shares of Inogen in the first quarter worth $255,000. Vanguard Group Inc. grew its position in Inogen by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock worth $11,492,000 after purchasing an additional 65,954 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in shares of Inogen during the 2nd quarter worth about $457,000. Divisadero Street Capital Management LP raised its position in shares of Inogen by 682.3% during the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after buying an additional 2,046,766 shares during the last quarter. Finally, Tocqueville Asset Management L.P. lifted its stake in shares of Inogen by 27.3% in the first quarter. Tocqueville Asset Management L.P. now owns 93,350 shares of the medical technology company’s stock valued at $753,000 after buying an additional 20,000 shares during the period. 89.94% of the stock is owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.